QUOTE AND NEWS
SeekingAlpha  Aug 21  Comment 
By JMY Investments: As the old adage goes; "Buy the rumor, sell the news." In the case of Advanced Cell Technology (OTCQB:ACTC), it was buy the rumor and sell the anticipation of the news. The stock went from a low of .0495 on June 16th to a high...
SeekingAlpha  Aug 12  Comment 
ByEsekla: Advanced Cell Technology (OTCQB:ACTC) held a conference call last night to provide a corporate update. It was the first opportunity for many to hear from the company's new CEO, Paul Wotton. Doctors Eddie Anglade and Robert Lanza also...
SeekingAlpha  Aug 7  Comment 
ByEsekla: Update: After this article was submitted, Advanced Cell Technology (OTCQB:ACTC) scheduled a conference call for Monday, August 11, 2014 at 5:00 p.m. This call could discuss DSMB (FDA Data Safety Monitoring Board) approval, publication of...
SeekingAlpha  Jul 2  Comment 
By Biotech Research Group: When I first wrote about Advanced Cell Technology (OTCQB:ACTC) in January of 2014, I was bullish. No doubt as to the content of my article, it was chock full of reasons why I believed that the company was going to...
StreetInsider.com  Jun 24  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/Advanced+Cell+Technology+%28ACTC%29+Taps+Antares+Pharma%27s+Wolton+as+CEO+%28ATRS%29/9608371.html for the full story.
SeekingAlpha  Jun 19  Comment 
By BiotechScout: The inflection point in the investment world reflects a significant change in the progress of a company, sector, industry, or economy. Once a dramatic change occurs, an inflection point can be considered a turning point, which can...
SeekingAlpha  Jun 11  Comment 
By JMY Investments: On Monday, June 9th, Advanced Cell Technology (OTCQB:ACTC) had a conference call to provide shareholders with a corporate update. The company is at a critical stage and the update provided valuable insight into how well...
SeekingAlpha  Apr 15  Comment 
By JMY Investments: My prior article, Advanced Cell Technology: A Key Patent Critique, created quite a buzz in Advanced Cell Technology (OTCQB:ACTC) investor circles. The article focused on ACTC's key patent #7,794,704 for hESC derived Retinal...
SeekingAlpha  Apr 8  Comment 
By JMY Investments: This is a follow up to my prior article: BioTime Joins Advanced Cell Technology In The AMD Race. A lot has happened in the three-week span since I wrote the article. Advanced Cell Technology (OTCQB:ACTC) filed their 10-K and...
SeekingAlpha  Apr 7  Comment 
ByEsekla: Advanced Cell Technology (OTCQB:ACTC) filed their annual 10-K report on Wednesday, after some delay. This massive, 145-page document goes beyond simple updates for the final quarter, and a summary of 2013; it restates financial data...




 

Advanced Cell Technology, Inc. is a biotechnology company that specializes in the development of cellular therapies for the treatment of rare and common diseases that impact millions of people worldwide. The company applies stem cell-based technologies and other proprietary methods in the area of regenerative medicine to bring patient-specific therapies from the lab to the bedside.

The Company is starting Phase 2 clinical trials for its Retinal Pigment Epithelial (RPE) program which addresses a number of retinal degenerative disorders (Macular Degeneration, Stargardt's disease). ACT has published positive data from animal studies for the RPE cell program – completed in collaboration with the Casey Eye Institute at Oregon Health and Science University (OHSU) – as well as recently announced promising results – also in collaboration with OHSU- from GLP Safety Studies and long-term efficacy studies for the RPE therapy. Currently ACT is finalizing preclinical studies for the bio-distribution of RPE and expects spiking studies to be finished in the second half of 2009. ACT expects to file the RPE program IND by the end of the year. Advanced Cell also has moved forward rapidly with it Hemangioblast (HG) platform. ACT has published positive data in the journal NATURE Methods for its HG cellular program for the treatment of blood and cardiovascular diseases. Additionally the company’s Myoblast program is an autologous adult stem cell therapy for the treatment of heart disease. The Myoblast program has successfully completed four Phase I clinical trials and has clearance from the FDA to begin Phase II trials.

In recent years ACT has announced the successful development of a novel technique to generate embryonic stem cell lines without destroying embryos, a breakthrough in the ethical debate surrounding the industry. Since then, the company has announced on multiple occasions the successful creation of human embryonic stem cell lines without the destruction or disruption of the developmental potential of the embryos. In support of its research and applications Advanced Cell owns or licenses over 380 patents and patent applications.

ACT is focused on three product areas.

1) The retinal pigment epithelium (RPE) program, which they believe will yield new therapies for treating disease indications and disorders such as age-related macular degeneration (AMD). The first therapeutic treatment using RPE therapy will be a treatment for Stargardt’s Disease. Along with our collaborators at the Casey Eye Institute at OHSU, the Company just announced a successful study results supporting the long-term safety and efficacy of our Retinal Disease therapy. ACT expects to file an IND by the end of 2009

2) The hemangioblast (HG) cell program could yield novel therapies for cardiac diseases such as heart failure has successfully completed Phase I human clinical trials. The program has clearance from the FDA to begin Phase II human clinical trials and ACT is currently seeking funding to support the initiation of a Phase II clinical trial.

3) The myoblast program which could yield novel therapies for cardiac diseases such as heart failure. It has successfully completed Phase I human clinical trials, and the program has clearance from the FDA to begin Phase II human clinical trials, ACT is currently seeking funding to support the initiation of a Phase II clinical trial.

Advanced Cell is led by an experienced management team and world-class scientific team, including CEO William Caldwell, Chief Scientific Officer Robert Lanza M.D., VP of Regulatory Ed Mickunas, Senior Director of Manufacturing Roger Gay PhD and our Director of Operations Rita Parker. The company operates a GMP-capable laboratory in Massachusetts and maintains offices in Southern California.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki